TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05156775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block (SPB)
Description: While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal nerve block (RIB)
Description: In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
Study: NCT05592639

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy
Description: Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy
Description: Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
Study: NCT06318494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: jumping performance
Description: Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: jumping performance
Description: Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal
Study: NCT05460143

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging scan
Description: Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
Study: NCT06061835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.
Description: Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release

Intervention type: OTHER
Group type: OTHER
Intervention: CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.
Description: Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release
Study: NCT04864951

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colli-Pee urine collection device
Description: first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
Study: NCT04386642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline solution in a clear 50-ml syringe
Study: NCT04891354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDNO
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDNO
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride (placebo)
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride (placebo)
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Study: NCT00430092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05351788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Study: NCT05346406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Peripheral Catheter
Description: Bard Powerglide 8 cm midline catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripherally Inserted Central Catheter
Description: Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
Study: NCT05351788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Study: NCT05313087

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine
Study: NCT05981690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided, parent-led CBT for preadolescent children with OCD
Description: This treatment was adapted from an existing evidence based therapist guided parent-led CBT intervention for preadolescent children with anxiety difficulties. It consists of 6 to 8 treatment individual treatment sessions where parents learn CBT techniques to apply at home with their child
Study: NCT05313087

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine
Study: NCT06422013

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GTB1
Description: oral administration of GTB1 powder packet once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo powder packet once daily
Study: NCT06330207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool
Description: The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
Study: NCT06154356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery therapy for rehabilitation
Description: Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham action observation and motor imagery therapy for rehabilitation
Description: Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions.
Study: NCT05429398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib Tablet
Description: 1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib.
Study: NCT04304872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed Financial Incentives
Description: Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed Financial Incentives
Description: Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
Study: NCT06259825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)
Description: At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control poultry foods (chicken-meat and eggs)
Description: At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
Study: NCT06273397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 MG
Description: Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone 2.5 MG
Description: Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Study: NCT05309148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on eye tracker based device
Description: The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training with a neuropsychologist
Description: The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on eye tracker based device and with a neuropsychologist
Description: This is combination of the first and second interventions
Study: NCT06288074

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-omics tests
Description: Biological sample collection for Multi-omics tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-omics tests
Description: Biological sample collection for Multi-omics tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-omics tests
Description: Biological sample collection for Multi-omics tests
Study: NCT06163222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional message with behavioural science-informed content and associated web pages
Description: Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional message with behavioural science-informed content and associated web pages
Description: Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional message with behavioural science-informed content and associated web pages
Description: Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual communication strategy
Description: Usual communications sent from outpatient services to remind participants about their appointments
Study: NCT05365126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complete Vocal Technique Voice Therapy
Description: A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
Study: NCT06300073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: U-shaped Power Toothbrush
Description: Twice daily brushing for 30 seconds with fluoride toothpaste

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: U-shaped Power Toothbrush
Description: Twice daily brushing for 30 seconds with fluoride toothpaste

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Soft Manual Toothbrush
Description: Twice daily brushing for 2 minutes with fluoride toothpaste

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Soft Manual Toothbrush
Description: Twice daily brushing for 2 minutes with fluoride toothpaste